Myelodysplastic Syndrome (MDS) is the most common bone marrow failure condition in the United States– it is referred to as pre-leukemia.
As a long-term survivor a multiple myeloma, another blood cancer, I have learned several things. First of all, conventional oncology often doesn’t spend much time and money research “pre-cancer.” And MDS is a form of pre-leukemia. Further, I’ve learned that pre-cancer may not require toxic chemotherapy regimens.
Just to be clear, I am not saying that it is bad that conventional oncology doesn’t spend much time on pre-cancers. I am saying this simply to caution patients and their caregivers. Do not be surprised when your oncologist tells you not to worry about your MDS diagnosis.
Lastly, I know that managing the toxicity of your therapy is critical. I believe that quality-of-life is just as important as quantity-of-life. The average MDS patient is 70 years old. This is not a group that handles toxicity very well.
The articles and studies linked below indicate that there are less toxic or non-toxic therapies for MDS.
I am both a cancer survivor and cancer coach. For more information on managing your MDS or any other question or comment scroll down the page and leave me a comment or question. I’ll reply ASAP.
“I have seen research for using both curcumin and CoQ10 in MDS. Since apoptosis is a large part of counts dropping particularly in the early stages of MDS, and these substances seem to increase apoptosis, I wondered if it was only to be used later. Although the research I read seemed to indicate it was for any stage. I did try them though and within just a couple weeks my hemoglobin and white counts dropped to their lowest ever for me…”
“MDS is the most common bone marrow failure condition in the United States; each year, between 12,000 to 15,000 people are diagnosed with the condition. Robin Roberts, an anchor with ABC’s Good Morning America, developed MDS after undergoing treatment for breast cancer. Roberts had a successful bone marrow transplant in 2012…
The patients received doses of the drug that was 75 to 90 percent lower than what is typically given to people as part of treatment for MDS.
What the researchers found: In 44 percent of patients in the trial, the disease was well controlled. Of that group, 20 percent remained on the drug for more than three years.”
“Naturally occurring compounds that are not toxic may provide a means to treat patients in the initial stages of the disease. We conducted a pilot study to test the efficacy of coenzyme Q10 (coQ10) in MDS patients with low to intermediate-2 risk disease. A variety of responses were observed in 7 of 29 patients including two trilineage and two cytogenetic responses…”
“Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogs can act on the differentiation and maturity of different cell lines…All the patients were in a low to intermediate risk group…
Treatment with vitamin D3 metabolites could induce a long-standing response of the hematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcemia.”
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”